🇺🇸 FDA

Intelligence · Clinical Pipeline

NovoThirteen Pipeline

All ClinicalTrials.gov programs at NovoThirteen — phase, modality, and trial IDs.

Programs
43

Quick answer

NovoThirteen has 43 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290

    NovoThirteen

    haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

    phase 3 small molecule active

    1 trial

  2. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290

    NovoThirteen

    Haemophilia A or B with or without inhibitors

    phase 3 small molecule active

    1 trial

  3. Concizumab C 40 mg/mL PDS290, Concizumab C 100 mg/mL PDS290

    NovoThirteen

    haemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

    phase 3 small molecule active

    1 trial

  4. Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity

    NovoThirteen

    Overweight and obesity

    phase 3 other active

    1 trial

  5. Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg

    NovoThirteen

    sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  6. Etavopivat A 200 mg

    NovoThirteen

    Sickle Cell Disease and Thalassaemia

    phase 3 small molecule active

    1 trial

  7. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  8. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Ozempic 2 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    NovoThirteen

    Participants with T2D and overweight

    phase 3 small molecule active

    1 trial

  9. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, insulin icodec 700 U/mL PDS290

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  10. Liraglutide placebo, Saxenda 6 mg/mL solution for injection in pre-filled pen

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  11. Mounjaro 5 mg solution for injection in pre-filled pen, cagrilintide semaglutide, cagrilintide semaglutide, Mounjaro 2.5 mg solution for injection in pre-filled pen, cagrilintide semaglutide

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  12. NNC0487-0111 B 10142, NNC0487-0111 B 10141, Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  13. NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10146, NNC0487-0111 B 10144

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  14. NNC0487-0111 B 10142, Placebo (NNC0487-0111), NNC0487-0111 B 10143, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10141

    NovoThirteen

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  15. NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  16. NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  17. NNC0487-0111 B 10146, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10141

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  18. NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10145, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  19. Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen

    NovoThirteen

    Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

    phase 3 small molecule active

    1 trial

  20. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  21. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide placebo, solution for injection in 1.5 mL pre-filled PDS290 pen injector

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  22. Placebo (ziltivekimab), ziltivekimab

    NovoThirteen

    Acute myocardial infarction

    phase 3 small molecule active

    1 trial

  23. Placebo (ziltivekimab), ziltivekimab

    NovoThirteen

    Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

    phase 3 small molecule active

    1 trial

  24. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  25. Placebo, Etavopivat A 200 mg

    NovoThirteen

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  26. Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  27. Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  28. Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  29. Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  30. Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  31. Semaglutide B 1.34 mg/mL PDS290 3.0 mL, Wegovy 2.4 mg solution for injection in pre-filled pen, Pre-filled syringe (glass) in a pre-filled pen: Semaglutide placebo Ia DV3396 pen-injector, 0.5 mL Semaglutide placebo Ib DV3396 pen-injector, 0.75 mL, Semaglutide B 0.68 mg/mL PDS290 1.5 mL, Semaglutide D 1.0 mg/mL DV3396, Semaglutide D 2.0 mg/mL DV3396, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Semaglutide B 3.2 mg/mL PDS290 3.0 mL

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  32. Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    NovoThirteen

    Growth Hormone Deficiency in children

    phase 3 small molecule active

    1 trial

  33. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  34. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  35. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Cardiovascular disease

    phase 3 small molecule active

    1 trial

  36. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, METFORMIN , INSULIN DEGLUDEC , INSULIN (HUMAN) , INSULIN GLARGINE , cagrilintide semaglutide, INSULIN DETEMIR , Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  37. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  38. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  39. cagrilintide, Placebo, cagrilintide, cagrilintide, cagrilintide

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  40. cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  41. coramitug C 10035, liquid dosage form in 20 mL vials with 11 extractable volume

    NovoThirteen

    Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy

    phase 3 small molecule active

    1 trial

  42. ziltivekimab, Placebo (ziltivekimab C)

    NovoThirteen

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial

  43. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does NovoThirteen have?

43 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.